论文部分内容阅读
目的探讨常规溶栓疗法并应用依达拉奉对心肌的保护作用。方法40例心梗患者中随机分为两组,观察组为常规溶栓时并应用依达拉奉0.5mg/kg、Bid,对照组为常规溶栓治疗。分别测定溶栓后2h、6h、48h血清乳酸脱氢酶(LDH)、磷酸肌酸激酶同工酶(CK-MB)、肌钙蛋白(CTnI)水平。结果观察组中LDH、CK-MB、CTnI均较对照组峰值提前(P<0.05)。结论依达拉奉可提高心肌细胞SOD活性,减少MDA产生,抑制脂质过氧化反应,减少心肌缺血再灌注损伤,促进心功能恢复,可作为心肌保护液的添加成分而有效减轻心梗中心肌缺血后再灌注损伤。
Objective To investigate the protective effect of edaravone on myocardium by conventional thrombolytic therapy. Methods Forty patients with myocardial infarction were randomly divided into two groups. The patients in the observation group were treated with edaravone 0.5 mg / kg and Bid, while the control group received conventional thrombolytic therapy. Serum levels of LDH, CK-MB and CTnI were measured at 2 hours, 6 hours and 48 hours after thrombolysis. Results The peak value of LDH, CK-MB and CTnI in the observation group was earlier than that in the control group (P <0.05). Conclusion Edaravone can improve myocardial SOD activity, reduce the production of MDA, inhibit lipid peroxidation, reduce myocardial ischemia-reperfusion injury and promote cardiac function recovery, which can be used as an additional component of myocardial protection solution and effectively reduce the myocardial infarction center Muscle ischemia and reperfusion injury.